DDInter1704 DDInter927
Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm in atrial fibrillation or flutter.[Label,L6373,L6376]
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Sotalol {u} (Compound) resembles {v} (Compound) Atenolol
Sotalol {u} (Compound) binds {v} (Gene) ADRB1
Sotalol {u} (Compound) is included by {v} (Pharmacologic Class) Cardiac Rhythm Alteration
Sotalol {u} (Compound) causes {v} (Side Effect) Ache
Sotalol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Sotalol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Kaolin
Sotalol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin degludec
Sotalol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thiethylperazine
Sotalol {u} may lead to a major life threatening interaction when taken with {v} Picosulfuric acid
Sotalol {u} may lead to a major life threatening interaction when taken with {v} Terfenadine
Sotalol (Compound) resembles Atenolol (Compound)
Sotalol (Compound) binds ADRB1 (Gene)
Sotalol (Compound) is included by Cardiac Rhythm Alteration (Pharmacologic Class)
Sotalol (Compound) causes Ache (Side Effect)
Sotalol may cause a minor interaction that can limit clinical effects when taken with Sucralfate
Sotalol may cause a minor interaction that can limit clinical effects when taken with Kaolin
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine
Sotalol may lead to a major life threatening interaction when taken with Picosulfuric acid
Sotalol may lead to a major life threatening interaction when taken with Terfenadine